Corporate Member Update: Merck- Keytruda®

Merck announces that KEYTRUDA® (pembrolizumab), in combination with chemotherapy, with or without bevacizumab, has been approved for the first-line treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express programmed death ligand 1 (PD-L1) (combined positive score [CPS] ≥1) as determined by an FDA-approved test.

To read the full press release, please click here!